Gene therapy is now
Oxford BioMedica annual report and accounts 2017
The latest annual report designed and produced by thinkerdoer for Oxford BioMedica tells the exciting story of the company and how it continues to lead the way un the gene and cell therapy sector. Of particular note is the key message section at the front of the book which provides an easy to digest overview of both Oxford BioMedica today and the gene and cell therapy market.
2017 was a milestone year for both Oxford BioMedica and the sector as it witnessed the first FDA approved gene and cell therapy treatment. Kymriah, a Novartis product targeting blood cancer uses Oxford BioMedica's LentiVector technology to work.
annual reports / investor communication materials